Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

This study found that various dietary supplements positively impacted hair density and were well-tolerated among patients with androgenetic alopecia, suggesting they may be useful adjuncts or alternatives to standard treatments.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

This study evaluated the efficacy of various skin graft types for burn injury healing, finding that xenografts had the highest repigmentation rate (87.50%), while device-facilitated autologous skin cell transplantation showed outstanding efficacy in reepithelialization, highlighting its potential in clinical practice.

Certain combination therapies, like microneedling with minoxidil, are more effective for female-pattern hair loss than other treatments.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In this study, a network meta-analysis found that treating lichen planopilaris with a combination of clobetasol, hydroxychloroquine, and N-acetylcysteine was the most effective approach, while cyclosporine, methotrexate, and some other treatments were less effective compared to hydroxychloroquine.

The study aims to find the best treatment for central serous chorioretinopathy by comparing various options.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study found that ALRV5XR showed the highest efficacy for terminal hair regrowth in both men and women with androgenetic alopecia, with less treatment resistance compared to other therapies.

Terbinafine 250 mg is the most effective treatment for fungal nail infections.

This study suggests platelet-rich plasma may be more effective than other non-surgical treatments for male androgenetic alopecia, while low-level laser therapy ranks highest for women; however, the evidence quality was low.

Results are not reported in this abstract, but it outlines the objective to evaluate the efficacy of microneedling, alone and in combination with other treatments, for pattern hair loss through a systematic review and meta-analysis.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This study systematically reviewed the literature on nonsurgical treatments for androgenetic alopecia, such as 5% minoxidil, platelet-rich plasma, and low-level laser therapy, but results on their relative effectiveness were not reported.

Prescription and alternative therapies for hair loss will be compared for effectiveness.

This study reviewed various studies and concluded that Janus kinase inhibitors, particularly tofacitinib, seem to promote hair regrowth in about half of patients with alopecia areata, though expected class-specific adverse effects were observed.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

This study evaluated the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male androgenetic alopecia and determined the relative efficacy of these therapies compared to topical minoxidil through a network meta-analysis.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This review guides readers on how to critically evaluate multiple treatment comparison meta-analyses, offering insights for interpreting and communicating these studies but reporting no new results.